Relutrigine (INN; developmental code name PRAX-562) is a persistentneuronalsodium channel blocker which is under development for the treatment of epilepsy and headache.[1][2][3] It is taken orally.[1] The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers.[2][3] Relutrigine is under development by Praxis Precision Medicines.[1][2] As of May 2026, it is in preregistration for epilepsy.[1] Conversely, no recent development has been reported for headaches.[1]
